Mobocertinib mesylate

• CAT Number: I032499
• CAS Number: 2389149-85-1
• Molecular Formula: C33H43N7O7S
• Molecular Weight: 681.81
• Purity: 98%
• Synonyms: Mobocertinib; TAK-788; TAK 788; TAK788; AP32788; AP-32788; AP 32788
• Target: Protein Tyrosine Kinase/RTK
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate mesylate
• InChI: InChI=1S/C32H39N7O4.CH4O3S/c1-9-29(40)34-24-16-25(28(42-8)17-27(24)38(6)15-14-37(4)5)35-32-33-18-22(31(41)43-20(2)3)30(36-32)23-19-39(7)26-13-11-10-12-21(23)26;1-5(2,3)4/h9-13,16-20H,1,14-15H2,2-8H3,(H,34,40)(H,33,35,36);1H3,(H,2,3,4)
• InChIKey: FYPXCXPAJAGDAI-UHFFFAOYSA-N
• SMILES: O=C(C1=CN=C(NC2=CC(NC(C=C)=O)=C(N(CCN(C)C)C)C=C2OC)N=C1C3=CN(C)C4=C3C=CC=C4)OC(C)C.OS(=O)(C)=O

Mobocertinib mesylate(CAT: I032499) is an oral, selective epidermal growth factor receptor (EGFR) inhibitor specifically designed to target EGFR exon 20 insertion mutations, which are common in certain forms of non-small cell lung cancer (NSCLC). By irreversibly binding to mutant EGFR, Mobocertinib inhibits downstream signaling pathways involved in tumor cell proliferation and survival. This targeted mechanism offers a promising treatment option for patients with EGFR-mutated NSCLC, particularly those resistant to standard EGFR inhibitors. Mobocertinib mesylate is a key compound in oncology research, advancing the development of precision therapies for difficult-to-treat lung cancers.